BR112023018652A2 - Formulação injetável de ação prolongada compreendendo risperidona e polímeros biodegradáveis - Google Patents

Formulação injetável de ação prolongada compreendendo risperidona e polímeros biodegradáveis

Info

Publication number
BR112023018652A2
BR112023018652A2 BR112023018652A BR112023018652A BR112023018652A2 BR 112023018652 A2 BR112023018652 A2 BR 112023018652A2 BR 112023018652 A BR112023018652 A BR 112023018652A BR 112023018652 A BR112023018652 A BR 112023018652A BR 112023018652 A2 BR112023018652 A2 BR 112023018652A2
Authority
BR
Brazil
Prior art keywords
risperidone
injectable formulation
long
biodegradable polymers
action
Prior art date
Application number
BR112023018652A
Other languages
English (en)
Portuguese (pt)
Inventor
Elgart Valitsky Anna
Merenlender Wagner Avia
Eran Harary
Original Assignee
Medincell S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medincell S A filed Critical Medincell S A
Publication of BR112023018652A2 publication Critical patent/BR112023018652A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR112023018652A 2021-03-17 2022-03-17 Formulação injetável de ação prolongada compreendendo risperidona e polímeros biodegradáveis BR112023018652A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163162272P 2021-03-17 2021-03-17
IB2021052248 2021-03-17
US202163208860P 2021-06-09 2021-06-09
US202163270174P 2021-10-21 2021-10-21
PCT/EP2022/057009 WO2022195018A1 (en) 2021-03-17 2022-03-17 Long acting injectable formulation comprising risperidone and biodegradable polymers

Publications (1)

Publication Number Publication Date
BR112023018652A2 true BR112023018652A2 (pt) 2023-10-03

Family

ID=81307068

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023018652A BR112023018652A2 (pt) 2021-03-17 2022-03-17 Formulação injetável de ação prolongada compreendendo risperidona e polímeros biodegradáveis

Country Status (10)

Country Link
US (2) US20240148641A1 (cg-RX-API-DMAC7.html)
EP (1) EP4308077A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024511353A (cg-RX-API-DMAC7.html)
KR (1) KR20230158088A (cg-RX-API-DMAC7.html)
AU (1) AU2022236485A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023018652A2 (cg-RX-API-DMAC7.html)
CA (1) CA3208006A1 (cg-RX-API-DMAC7.html)
IL (1) IL304980A (cg-RX-API-DMAC7.html)
MX (1) MX2023010925A (cg-RX-API-DMAC7.html)
WO (1) WO2022195018A1 (cg-RX-API-DMAC7.html)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010313290A1 (en) * 2009-10-30 2012-05-17 Janssen Pharmaceutica Nv Dosing regimen associated with long-acting injectable paliperidone esters
US10463607B2 (en) * 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
KR101424163B1 (ko) * 2010-12-24 2014-08-01 주식회사 삼양바이오팜 수난용성 약물 함유 서방성 마이크로입자 및 그 제조방법
MY165655A (en) 2010-12-29 2018-04-18 Medincell Biodegradable drug delivery compositions
KR102189442B1 (ko) 2012-06-27 2020-12-11 메딘셀 에스.에이. 소수성 조성물용 생분해성 약물 전달
US20190015415A1 (en) * 2015-09-30 2019-01-17 Indivior Uk Limited Methods for treating schizophrenia
CN107213136B (zh) * 2017-06-07 2021-06-01 广州帝奇医药技术有限公司 一种长效缓释药物制剂及其制备方法
US20210386745A1 (en) * 2019-01-22 2021-12-16 Indivior Uk Limited Methods for treating schizophrenia
SI4027973T1 (sl) * 2019-09-13 2026-02-27 Medincell S.A. Formulacije za dostavo zdravil

Also Published As

Publication number Publication date
AU2022236485A1 (en) 2023-08-24
US12329851B2 (en) 2025-06-17
US20240148641A1 (en) 2024-05-09
IL304980A (en) 2023-10-01
KR20230158088A (ko) 2023-11-17
WO2022195018A1 (en) 2022-09-22
JP2024511353A (ja) 2024-03-13
US20240325293A1 (en) 2024-10-03
EP4308077A1 (en) 2024-01-24
MX2023010925A (es) 2023-09-27
CA3208006A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
D. Levin α7-Nicotinic receptors and cognition
PH12020500265A1 (en) Indole carboxamides compounds useful as kinase inhibitors
SA521430792B1 (ar) مركبات مضادة للفيروسات محتوية على نيتريل
BRPI0520588B8 (pt) uso de composições farmacêuticas para o tratamento de doenças do ouvido interno
DE60321929D1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DE60222137D1 (de) Zuckerderivate von hydromorphon, dihydromorphin und dihydroisomorphin, zusammensetzungen davon und verwendung zur vorbeugung und behandlung von schmerzen
BR112015031432A2 (pt) compostos de carbazol carboxamida úteis como inibidores de cinase
ATE401874T1 (de) Verabreichung von capsaicinoiden
EP4342532A3 (en) Antiplatelet drugs and uses thereof
BR112015030723A2 (pt) compostos de tetra-hidrocarbazol e carbazol carboxamida substituídos úteis como inibidores da quinase
BR112023016678A2 (pt) Inibidores de tyk2 e usos dos mesmos
BR112022004535A2 (pt) Formulações de entrega de fármaco
BR112021021826A8 (pt) Uso de apremilaste e um inibidor da tirosina quinase 2 no tratamento de uma doença ou um transtorno responsivo à inibição da fosfodiesterase tipo 4
MX2021003150A (es) Agentes monomericos y multimericos contra el vhb.
BR112023002295A2 (pt) Terapia de combinação
JP2018504984A5 (cg-RX-API-DMAC7.html)
BR112022021957A2 (pt) Imidazopirimidinas como moduladores de il -17
ATE544354T1 (de) Vermeidung und behandlung von mikrobenübertragenen epithelerkrankungen
WO2021232067A8 (en) Stat3 inhibition for treatment and prevention of human coronavirus infection
BR112019018615A2 (pt) compostos antimicrobianos, composições e usos dos mesmos
TWI612965B (zh) 玻尿酸之用途及疼痛抑制用醫藥組成物
EA202090242A1 (ru) Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов
WO2022192594A3 (en) Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease
AR110800A1 (es) MÉTODOS PARA AUMENTAR EN PLASMA SANGUÍNEO LA 2’-DESOXIURIDINA (dUrd) Y LA INHIBICIÓN DE LA TIMIDILATO SINTASA
DE60124387D1 (de) Synergistische kombination zur behandlung von kolorektalkarzinom